U.S. regulators are considering extending their approval of Pfizer’s rheumatoid arthritis therapy Xeljanz to ulcerative colitis as well. That possibility surfaced when the Food and Drug Administration accepted Pfizer’s supplemental New Drug Application for Xeljanz ... Read more